obliterans

ob·lit·e·rans

(ob-lit'ĕ-ranz)
Obliterating.
[L.]
References in periodicals archive ?
"Flavoured e-cigarettes often contain a chemical compound called diacetyl, which is associated with a rare lung disease called bronchiolitis obliterans that causes permanent damage to the bronchioles (the tiniest airways in the lungs)," said Dr Sreedharan
The lead product candidate, L-CsA-i, has currently started two global phase 3 clinical studies for treatment of bronchiolitis obliterans syndrome (BOS) post-lung transplantation, a fatal respiratory orphan disease with no therapies approved.
InBuerger's disease also called thromboangiitis obliterans the blood vessels become inflamed, swell, and can become blocked with blood clots.
Among the physical risks is exposure to harmful chemicals (even if less numerous than smoked tobacco products) such as diacetyl (a known cause of bronchiolitis obliterans, or "popcorn lung"), formaldehyde, acrolein, benzene, and metals such as nickel, tin, and lead.
M2 PHARMA-March 26, 2019-Breath Therapeutics begins global Phase 3 trials of La[euro]'CsAa[euro]'i for treating Bronchiolitis Obliterans Syndrome
Food & Drug Administration describing a case in which one of her patients was diagnosed with the debilitating lung disease Broncholitis obliterans. Dr.
The other name for Buerger's is thrombo-angiitis obliterans, which describes the pathology more vividly.
Sulfasalazine-induced pulmonary toxicity may manifest in various forms, including subacute interstitial pneumonia, pulmonary infiltration with eosinophilia, desquamative interstitial pneumonia, bronchiolitis obliterans organizing pneumonia, acute pulmonary edema, eosinophilic pleural effusion, pleural/pericardial hemorrhage or effusion, and antinuclear and anti-histone antibody positivity [I, 3].
In a clinical trial, azithromycin was being used to prevent bronchiolitis obliterans syndrome in patients with cancers of the blood or lymph nodes who underwent a donor stem cell transplant.
Thromboangiitis obliterans (TAO), or Buerger's disease, is a rare nonatherosclerotic disease that affects the medium and small arteries.
Mochida is an integrated Japanese pharmaceutical company that developed and markets a prescription pure EPA drug product, Epadel, as a treatment for hyperlipidemia and arteriosclerosis obliterans in Japan.